News and Announcements
Biotech Head, Leslie Chong Has Described Female Chiefs as “Unicorns”
- Published March 06, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Leslie Chong, Chief Executive of Australian-listed drug developer, Imugene, has spoken out about the idea of the glass ceiling as she believes there are plenty of capable women out there but for “whatever reason” men hold most CEO positions in the science and tech industry.
KEY TAKEAWAYS:
- Ms Chong is hoping she can reverse this trend as she helps her company break new ground in cancer drugs.
– Ms Chong has developed in this sector over 19 years, with hopes to lead the way in immo-oncology treatments and her quest is personal as her father died from gastric cancer.
– “What turned into a purely-financial itch, or means to get by, has turned into a passion”.
- Imugene’s work is centred around the HER 2 receptor which is present in about 20 per cent of gastric and breast cancers.
- The Company is developing a B-cell vaccine designed to stimulate a patient’s own immune system to produce antibodies to repeatedly attack the cancer.
“When I have to present to a large audience, I can’t help but say to the audience that ‘I’m the only women presenting today, you need to ask yourself why’,” she said. “That is important to me. I understand what I may represent for the rest of the people. I’m not trying to make myself a martyr but I do think it’s harder and I do have to be better — that could be self-driven but it could also be socially driven as well.
“On a daily basis I wake up and think, I’m a woman CEO of a biotech company … I’m humbled by it and feel I have to work harder because of that, because I’m representing here, in a lot of ways.”
“Imugene was in that niche area, where they are taking good technology and trying to put that in the forefront of a biotech development company.”
Imugene is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.
Company Updates
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Material gains: Swinburne spin-out EntroMat takes aim at $160b global market
Traditional metallurgy has hit a performance wall. Discover how Swinburne University spin-out EntroMat is leveraging physics-based AI and circular critical minerals to engineer high-entropy alloys capable of surviving the world’s most extreme industrial environments.
Backed By Leading Investment Groups and Family Offices
